The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESSO 44 | Innovative intraperitoneal therapy strategies for peritoneal metastases
Wim Ceelen, MD, PhD, Ghent University Hospital, Ghent, Belgium, discusses novel methods to deliver intraperitoneal therapy, including immune therapy and immune-modulating therapies to alter the immune microenvironment of peritoneal metastasis in colorectal cancer. Prof. Ceelen highlights the potential of combining intraperitoneal immune modulators with systemic immune checkpoint inhibitors and the use of radionuclide therapy, such as radium-223, for intraperitoneal delivery in ovarian cancer, as well as physical methods like electrical currents to enhance drug delivery. This interview took place at the 44th Congress of the European Society of Surgical Oncology (ESSO 44) in Gothenburg, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yes, so the session was about novel methods to deliver intraperitoneal therapy. The first topic was immune therapy and immune-modulating therapies. So we have been discussing the immune microenvironment of peritoneal metastasis and specifically focusing on colorectal cancer. And then we have been discussing ways to, in fact, try to change this immune microenvironment by delivering either immune modulators intraperitoneally or combining this with systemic immune checkpoint inhibitors and trying to make the tumor sensitive to immune checkpoint inhibitors...
Yes, so the session was about novel methods to deliver intraperitoneal therapy. The first topic was immune therapy and immune-modulating therapies. So we have been discussing the immune microenvironment of peritoneal metastasis and specifically focusing on colorectal cancer. And then we have been discussing ways to, in fact, try to change this immune microenvironment by delivering either immune modulators intraperitoneally or combining this with systemic immune checkpoint inhibitors and trying to make the tumor sensitive to immune checkpoint inhibitors. And then another topic in the session was the use of radionuclide therapy, specifically using an alpha-emitting particle, radium-223. And there were some exciting preliminary results presented by, in fact, a small company, which is developing this type of novel radionuclide therapy for intraperitoneal delivery. And they are specifically focusing on ovarian cancer, and the results seem to be quite promising. Another topic that was addressed also by myself is the use of physical methods to enhance the efficacy of intraperitoneal drug delivery and this can be done by, for instance, using electrical currents and where we can use electrostatic precipitation or electromotive drug administration to drive the drug into the tissue. That was another topic of this innovative session.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
